Cholera ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Cholera ' Pipeline Review, H2 2012
Published on September 2012

Report Summary


Summary

Global Markets Direct's, 'Cholera - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for Cholera, complete with latest updates, and special features on
late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cholera. Cholera -
Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Cholera.
- A review of the Cholera products under development by companies and universities/research institutes based on information derived
from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cholera pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cholera.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content

Cholera ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cholera Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cholera 7
Cholera Therapeutics under Development by Companies 9
Cholera Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Early Clinical Stage Products 13
Pre-Clinical Stage Products 14
Cholera Therapeutics ' Products under Development by Companies 15
Cholera Therapeutics ' Products under Investigation by Universities/Institutes 16
Companies Involved in Cholera Therapeutics Development 17
Napo Pharmaceuticals, Inc. 17
Vaccine Technologies, Inc. 18
PaxVax 19
Cholera ' Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
crofelemer - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Peru-15 - Drug Profile 27
R&D Progress 27
Bivalent Killed Oral Cholera Vaccine - Drug Profile 28
R&D Progress 28
Cholera Toxin B - Drug Profile 29
R&D Progress 29
Dukoral Vaccine - Drug Profile 30



R&D Progress 30
PXVX-0200 - Drug Profile 31
R&D Progress 31
Cholera Therapeutics ' Drug Profile Updates 32
Cholera Therapeutics - Dormant Products 35
Cholera ' Product Development Milestones 36
Featured News & Press Releases 36
Mar 19, 2012: FDA Accepts PaxVax's IND For Single-Dose Oral Cholera Vaccine 36
Aug 26, 2008: Crucell to move Dukoral and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites 36
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 37
Feb 25, 2003: Dukoral Approved In Canada 38
Mar 11, 2002: European Marketing Authorisation Application Submitted For Dukoral 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables

Number of Products Under Development for Cholera, H2 2012 7
Products under Development for Cholera ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Napo Pharmaceuticals, Inc., H2 2012 17
Vaccine Technologies, Inc., H2 2012 18
PaxVax, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Cholera Therapeutics ' Drug Profile Updates 32
Cholera Therapeutics ' Dormant Products 35

List of Figures

Number of Products under Development for Cholera, H2 2012 7



Products under Development for Cholera ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Cholera ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Cholera ' Pipeline Review, H2 2012